FDA Places Clinical Hold on Phase 2 Study of PGN-EDO51 in Duchenne Muscular Dystrophy

As of July 2024, 2 participants in the ongoing CONNECT1 study have received 4 doses of PGN-EDO51 at 10 mg/kg, which has been generally well tolerated, with initial results expected in early 2025.:

Source: Neurology Read More

Previous PostNeuroVoices: Barry Ticho, MD, PhD, on the Disease-Modifying Potential of STK-001 in Treating Dravet Syndrome
Next PostNovel Approach to Antiseizure Drug Development With Use of Long Episodes: Jacqueline A. French, MD

FDA Places Clinical Hold on Phase 2 Study of PGN-EDO51 in Duchenne Muscular Dystrophy

Previous PostNeuroVoices: Barry Ticho, MD, PhD, on the Disease-Modifying Potential of STK-001 in Treating Dravet Syndrome

Next PostNovel Approach to Antiseizure Drug Development With Use of Long Episodes: Jacqueline A. French, MD

Related Posts

<![CDATA[Targeting IDH and 2-HG: Mechanistic Links Between Tumor Biology and Seizure Activity]]>

<![CDATA[Seizure Burden in IDH-Mutant Glioma: Impact on Daily Function and Quality of Life]]>

<![CDATA[FDA Approves AXS-05 as New Treatment for Alzheimer Disease Agitation]]>

Categories